2014•Hebei yixueRequires access

The Efficacy of Rituximab Combined with CHOP for Non-Hodgkin's Lymphoma

Wei Ta

Abstract

Objective: To investigate the effect of rituximab combined with CHOP for non-Hodgkin's lymphoma. Methods: 48 patients with non-Hodgkin's lymphoma were divided into experimental group( 24cases) and control group( 24 cases) randomly. The patients in control group were treated with CHOP regimen alone,and those in experimental group received rituximab combined with CHOP regimen. The response rate and adverse reaction were compared between two groups. Results: Patients got complete remission( CR) and partial remission( PR) were 11 cases and 8 cases,and total response rate was 79. 2% in experimental group. And the numbers were 7 cases and 6 cases,and total response rate was 54. 2% in control group. The therapeutic differences between two groups showed a statistical significance( P0. 05). But the rates of adverse reaction was similiar( P0. 05). Conclusion: Compared with CHOP regimen chemotherapy,rituximab combined with CHOP regimen shows better therapeutic effect without creasing the adverse reaction.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Medicine, Rituximab, Regimen, CHOP, Lymphoma, Adverse effect, Internal medicine, Gastroenterology